Leitlinie des Berufsverbands der Augenärzte Deutschlands e. V. und der Deutschen Ophthalomologischen Gesellschaft: Leitlinie Nr. 24a: Uveitis intermedia (Stand: Juli 2014)^[*]

Uveitis intermedia

Leitlinien sind Orientierungshilfen im Sinne von „Handlungs- und Entscheidungskorridoren“, von denen in begründeten Fällen abgewichen werden kann oder sogar muss. Sie beschreiben, was Augenärzte für eine angemessene Patientenversorgung in der Praxis für geboten halten. Dies entspricht in vielen Fällen nicht dem Leistungsniveau der gesetzlichen Krankenversicherung in Deutschland (siehe Präambel).

^* Dieser Beitrag wird ebenfalls in der Zeitschrift Der Ophthalmologe, Springer-Verlag, Berlin Heidelberg 2014, 10.1007/s00347-014-3198-6 veröffentlicht.

• Literatur

• 1 Jabs DA, Nussenblatt RB, Rosenbaum JT. Standardization of uveitis nomenclature for reporting clinical data. Results of the First International Workshop. Am J Ophthalmol 2005; 140: 509-516
• 2 Suhler EB, Lloyd MJ, Choi D et al. Incidence and prevalence of uveitis in Veterans Affairs Medical Centers of the Pacific Northwest. Am J Ophthalmol 2008; 146: 890e8-896e8
• 3 Darrell RW, Wagener HP, Kurland LT. Epidemiology of uveitis. Incidence and prevalence in a small urban community. Arch Ophthalmol 1962; 68: 502-514
• 4 Gritz DC, Wong IG. Incidence and prevalence of uveitis in Northern California; the Northern California Epidemiology of Uveitis Study. Ophthalmology 2004; 111: 491-500 (discussion 500)
• 5 Mortensen KK, Goldschmidt SA, Uveitis E. Eine epidemiologische Untersuchung. Ber Dtsch Ophthalmol Ges 1981; 78: 97-101
• 6 Vadot E. Epidemiology of intermediate uveitis: a prospective study in Savoy. Dev Ophthalmol 1992; 23: 33-34
• 7 Tran VT, Auer C, Guex-Crosier Y et al. Epidemiological characteristics of uveitis in Switzerland. Int Ophthalmol 1994; 18: 293-298
• 8 Saari KM, Paivonsalo-Hietanen T, Vaahtoranta-Lehtonen H et al. Epidemiology of endogenous uveitis in south-western Finland. Acta Ophthalmol Scand 1995; 73: 345-349
• 9 Miettinen R. Incidence of uveitis in Northern Finland. Acta Ophthalmol 1977; 55: 252-260
• 10 Manthey KF. Intraokuläre Entzündungen. Stuttgart: Ferdinand Enke; 1988
• 11 Jakob E, Reuland MS, Mackensen F et al. Uveitis subtypes in a german interdisciplinary uveitis center–analysis of 1916 patients. J Rheumatol 2009; 36: 127-136
• 12 McCannel CA, Holland GN, Helm CJ et al. Causes of uveitis in the general practice of ophthalmology. UCLA Community-Based Uveitis Study Group. Am J Ophthalmol 1996; 121: 35-46
• 13 Boskovich SA, Lowder CY, Meisler DM et al. Systemic diseases associated with intermediate uveitis. Cleve Clin J Med 1993; 60: 460-465
• 14 Bonfioli AA, Damico FM, Curi AL et al. Intermediate uveitis. Semin Ophthalmol 2005; 20: 147-154
• 15 Vidovic-Valentincic N, Kraut A, Hawlina M et al. Intermediate uveitis: long-term course and visual outcome. Br J Ophthalmol 2009; 93: 477-480
• 16 Malinowsk SM, Pulido JS, Folk JC. Long-term visual outcome and complications associated with pars planitis. Ophthalmology 1993; 100: 818-824 (discussion 825)
• 17 Fearnley IR, Rosenthal AR. Fuchsʼ heterochromic iridocyclitis revisited. Acta Ophthalmol Scand 1995; 73: 166-170
• 18 Jones NP. Fuchsʼ Heterochromic Uveitis: a reappraisal of the clinical spectrum. Eye (Lond) 1991; 5: 649-661
• 19 Mandeville JT, Levinson RD, Holland GN. The tubulointerstitial nephritis and uveitis syndrome. Surv Ophthalmol 2001; 46: 195-208
• 20 Donaldson MJ, Pulido JS, Herman DC et al. Pars planitis: a 20-year study of incidence, clinical features, and outcomes. Am J Ophthalmol 2007; 144: 812-817
• 21 Nussenblatt RB, Palestine AG, Chan CC et al. Standardization of vitreal inflammatory activity in intermediate and posterior uveitis. Ophthalmology 1985; 92: 467-471
• 22 Ang M, Hedayatfar A, Zhang R et al. Clinical signs of uveitis associated with latent tuberculosis. Clin Experiment Ophthalmol 2012; 40: 689-696
• 23 Quentin CD, Reiber H. Fuchs heterochromic cyclitis: rubella virus antibodies and genome in aqueous humor. Am J Ophthalmol 2004; 138: 46-54
• 24 de Groot-Mijnes JD, de Visser L, Rothova A et al. Rubella virus is associated with fuchs heterochromic iridocyclitis. Am J Ophthalmol 2006; 141: 212-214
• 25 Roesel M, Gutfleisch M, Heinz C et al. Intravitreal and orbital floor triamcinolone acetonide injections in noninfectious uveitis: a comparative study. Ophthalmic Res 2009; 42: 81-86
• 26 Bae JH, Lee CS, Lee SC. Efficacy and safety of intravitreal bevacizumab compared with intravitreal and posterior sub-tenon triamcinolone acetonide for treatment of uveitic cystoid macular edema. Retina 2011; 31: 111-118
• 27 Kok H, Lau C, Maycock N et al. Outcome of intravitreal triamcinolone in uveitis. Ophthalmology 2005; 112: 1916e1-e7
• 28 Angunawela RI, Heatley CJ, Williamson TH et al. Intravitreal triamcinalone acetonide for refractory uveitic cystoid macular oedema: longterm management and outcome. Acta Ophthalmol Scand 2005; 83: 595-599
• 29 Lowder C, Belfort jr. R, Lightman S et al. Dexamethasone intravitreal implant for noninfectious intermediate or posterior uveitis. Arch Ophthalmol 2011; 129: 545-553
• 30 Winterhalter S, Ruokonen P, van der Velden KH et al. [Intravitreal implants: drug carriers and carriers of hope?]. Ophthalmologe 2011; 108: 222-229
• 31 Jaffe GJ, Martin D, Callanan D et al. Fluocinolone acetonide implant (Retisert) for noninfectious posterior uveitis: thirty-four-week results of a multicenter randomized clinical study. Ophthalmology 2006; 113: 1020-1027
• 32 Callanan DG, Jaffe GJ, Martin DF et al. Treatment of posterior uveitis with a fluocinolone acetonide implant: three-year clinical trial results. Arch Ophthalmol 2008; 126: 1191-1201
• 33 Kempen JH, Altaweel MM, Holbrook JT et al. The multicenter uveitis steroid treatment trial: rationale, design, and baseline characteristics. Am J Ophthalmol 2010; 149: 550e10-561e10
• 34 de Smet MD. Corticosteroid intravitreal implants. Dev Ophthalmol 2012; 51: 122-133
• 35 Soheilian M, Rabbanikhah Z, Ramezani A et al. Intravitreal bevacizumab versus triamcinolone acetonide for refractory uveitic cystoid macular edema: a randomized pilot study. J Ocul Pharmacol Ther 2010; 26: 199-206
• 36 Cunningham jr. ET, Wender JD. Practical approach to the use of corticosteroids in patients with uveitis. Can J Ophthalmol 2010; 45: 352-358
• 37 Taylor SR, Isa H, Joshi L et al. New developments in corticosteroid therapy for uveitis. Ophthalmologica 2010; 224 (Suppl. 01) S46-S53
• 38 Whitcup SM et al. A randomized, masked, cross-over trial of acetazolamide for cystoid macular edema in patients with uveitis. Ophthalmology 1996; 103: 1054-1062 (discussion 1062–1063)
• 39 Schilling H, Heiligenhaus A, Laube T et al. Long-term effect of acetazolamide treatment of patients with uveitic chronic cystoid macular edema is limited by persisting inflammation. Retina 2005; 25: 182-188
• 40 Jabs DA, Rosenbaum JT, Foster CS et al. Guidelines for the use of immunosuppressive drugs in patients with ocular inflammatory disorders: recommendations of an expert panel. Am J Ophthalmol 2000; 130: 492-513
• 41 Esterberg E, Acharya NR. Corticosteroid-sparing therapy: practice patterns among uveitis specialists. J Ophthalmic Inflamm Infect 2012; 2: 21-28
• 42 de Vries J, Baarsma GS, Zaal MJ et al. Cyclosporin in the treatment of severe chronic idiopathic uveitis. Br J Ophthalmol 1990; 74: 344-349
• 43 Kacmaz RO, Kempen JH, Newcomb C et al. Cyclosporine for ocular inflammatory diseases. Ophthalmology 2010; 117: 576-584
• 44 Nussenblatt RB, Palestine AG, Chan CC et al. Randomized, double-masked study of cyclosporine compared to prednisolone in the treatment of endogenous uveitis. Am J Ophthalmol 1991; 112: 138-146
• 45 Gangaputra S, Newcomb CW, Liesegang TL et al. Methotrexate for ocular inflammatory diseases. Ophthalmology 2009; 116: 2188e1-2198e1
• 46 Malik AR, Pavesio C. The use of low dose methotrexate in children with chronic anterior and intermediate uveitis. Br J Ophthalmol 2005; 89: 806-808
• 47 Teoh SC, Hogan AC, Dick AD et al. Mycophenolate mofetil for the treatment of uveitis. Am J Ophthalmol 2008; 146: 752-760 760e1–3
• 48 Galor A, Jabs DA, Leder HA et al. Comparison of antimetabolite drugs as corticosteroid-sparing therapy for noninfectious ocular inflammation. Ophthalmology 2008; 115: 1826-1832
• 49 Thorne JE, Jabs DA, Qazi FA et al. Mycophenolate mofetil therapy for inflammatory eye disease. Ophthalmology 2005; 112: 1472-1477
• 50 Doycheva D, Deuter C, Blumenstock G et al. Long-term results of therapy with mycophenolate mofetil in ocular mucous membrane pemphigoid. Ocul Immunol Inflamm 2011; 19: 431-438
• 51 Abu El-Asrar AM, Hemachandran S, Al-Mezaine HS et al. The outcomes of mycophenolate mofetil therapy combined with systemic corticosteroids in acute uveitis associated with Vogt-Koyanagi-Harada disease. Acta Ophthalmol 2012; 90: e603-e608
• 52 Doycheva D, Zierhut M, Blumenstock G et al. Mycophenolate mofetil in the therapy of uveitic macular edema–long-term results. Ocul Immunol Inflamm 2012; 20: 203-211
• 53 Lau CH, Comer M, Lightman S. Long-term efficacy of mycophenolate mofetil in the control of severe intraocular inflammation. Clin Experiment Ophthalmol 2003; 31: 487-491
• 54 Siepmann K, Huber M, Stubiger N et al. Mycophenolate mofetil is a highly effective and safe immunosuppressive agent for the treatment of uveitis : a retrospective analysis of 106 patients. Graefes Arch Clin Exp Ophthalmol 2006; 244: 788-794
• 55 Murphy CC, Greiner K, Plskova J et al. Cyclosporine vs. tacrolimus therapy for posterior and intermediate uveitis. Arch Ophthalmol 2005; 123: 634-641
• 56 Hogan AC, McAvoy CE, Dick AD et al. Long-term efficacy and tolerance of tacrolimus for the treatment of uveitis. Ophthalmology 2007; 114: 1000-1006
• 57 Pacheco PA, Taylor SR, Cuchacovich MT et al. Azathioprine in the management of autoimmune uveitis. Ocul Immunol Inflamm 2008; 16: 161-165
• 58 Yazici H, Pazarli H, Barnes CG et al. A controlled trial of azathioprine in Behcetʼs syndrome. N Engl J Med 1990; 322: 281-285
• 59 Greenwood AJ, Stanford MR, Graham EM. The role of azathioprine in the management of retinal vasculitis. Eye (Lond) 1998; 12: 783-788
• 60 Roy M. Early clinical experience with leflunomide in uveitis. Can J Ophthalmol 2007; 42: 634
• 61 Molina C, Modesto C, Martin-Begué N et al. Leflunomide, a valid and safe drug for the treatment of chronic anterior uveitis associated with juvenile idiopathic arthritis. Clin Rheumatol 2013; 32: 1673-1675
• 62 Mackensen F, Max R, Becker MD. Interferons and their potential in the treatment of ocular inflammation. Clin Ophthalmol 2009; 3: 559-566
• 63 Deuter C, Stubiger N, Zierhut M. Interferon-alpha therapy in noninfectious uveitis. Dev Ophthalmol 2012; 51: 90-97
• 64 Mackensen F, Jakob E, Springer C et al. Interferon versus methotrexate in intermediate uveitis with macular edema: results of a randomized controlled clinical trial. Am J Ophthalmol 2013; 156: 478e1-486e1
• 65 Missotten T, van Laar JA, van der Loos TL et al. Octreotide long-acting repeatable for the treatment of chronic macular edema in uveitis. Am J Ophthalmol 2007; 144: 838-843
• 66 Cordero-Coma M, Yilmaz T, Onal S. Systematic review of anti-tumor necrosis factor-alpha therapy for treatment of immune-mediated uveitis. Ocul Immunol Inflamm 2013; 21: 12-20
• 67 Rubbert-Roth A. Assessing the safety of biologic agents in patients with rheumatoid arthritis. Rheumatology (Oxford) 2012; 51 (Suppl. 05) v38-v47
• 68 Becker M, Davis J. Vitrectomy in the treatment of uveitis. Am J Ophthalmol 2005; 140: 1096-1105